Mefloquine

The combination of AVA and MQ therapy led to a significant delay in mouse mortality.

A series of novel thioetherhydroxyethylsulfonamide derivatives has been synthesized from the coupling of intermediates 3-amino-4-phenyl-1-thioetherazine-butan-2-oles 6,7 with arenesulfonyl chlorides in good yields.

Currently available data provide a scientific basis for the use of mefloquine in small children in the chemoprophylaxis setting and as a part of treatment regimens in children living in endemic areas.

Multidrug-resistant Plasmodium falciparum malaria parasites pose a threat to effective drug control, even to artemisinin-based combination therapies (ACTs).

Our study shows that MQ + AS is highly efficacious in the Peruvian Amazon.

A shorter post-travel regimen has a significant impact on adherence to antimalarial prophylaxis. A reassessment of the risk by travelers on returning home may be a major contributor to this poor adherence.

Reduction of CNS levels of NGQMs relative to mefloquine may be feasible. Optimization of this property together with potency and long half-life may be feasible amongst diamine quinoline methanols.

A significant intersection between antimalarial and antiprion activity is well established for certain compound classes, specifically for polycyclic antimalarial agents bearing basic nitrogen-containing sidechains (e.g., chloroquine, quinacrine, mefloquine).

We conclude that malaria infection during suppressive prophylaxis does not induce antibody response to the blood-stage antigen MSP142 in a malaria-naïve study population.

Four 5-carbon-linked trioxane dimer orthoesters (6a–6d) have been prepared in 4 or 5 chemical steps from the natural trioxane artemisinin (1).